Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03708627 · ClinicalTrials.gov registry record · Early Phase 1
Bimatoprost as a Treatment for Graves' Orbitopathy
A Early Phase 1 study of Graves Ophthalmopathy, sponsored by Johns Hopkins University.
- Recruiting
- Registry status
- Early Phase 1
- Development phase
- 3
- Enrollment target
- 1
- Study location
NCT03708627: Recruiting Early Phase 1 study of Graves Ophthalmopathy, sponsored by Johns Hopkins University.
NCT03708627 is a Early Phase 1 study of Graves Ophthalmopathy that is actively recruiting participants, run by Johns Hopkins University. The registered enrollment target is 3 participants, below the 88-participant average among 3 other Graves Ophthalmopathy trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03708627, a Early Phase 1 study of Graves Ophthalmopathy, is actively recruiting participants, sponsored by Johns Hopkins University.
- RECRUITING
- Registry status
- Early Phase 1
- Development phase
- 3 participants
- Enrollment target
- 1
- Study location
Study Summary
Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
Conditions Studied
Interventions
- DRUG Bimatoprost Ophthalmic
Study Locations (1)
Washington
- University of Washington - Seattle
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 3 participants |
| Start Date | 2017-11-01 |
| Est. Completion | 2031-07-01 |
| Phase | Early Phase 1 |
What NCT03708627 shows while recruiting
NCT03708627 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 3 participants, a relatively small participant target, below the 88-participant average among 3 other Graves Ophthalmopathy trials with a reported enrollment target (97% lower).
The record links to 1 condition, with Graves Ophthalmopathy appearing as the primary indexed condition, and to 1 intervention - of which Bimatoprost Ophthalmic is the first listed.
NCT03708627 reports a single indexed study location in Washington.
Frequently Asked Questions
What is clinical trial NCT03708627 about?
NCT03708627 is a clinical study titled "Bimatoprost as a Treatment for Graves' Orbitopathy". Testing whether Bimatoprost, a topical eye drop used for glaucoma, can be used to induce periorbital fat atrophy in patients with Graves' disease
What is the current status of trial NCT03708627?
This trial is currently recruiting. It is a Early Phase 1 study. The enrollment target is 3 participants. The study started on 2017-11-01. Estimated completion is 2031-07-01.
What conditions does trial NCT03708627 study?
This clinical trial studies the following conditions: Graves Ophthalmopathy.
What interventions are being tested in trial NCT03708627?
The interventions under investigation include: Bimatoprost Ophthalmic (DRUG).
Who is sponsoring clinical trial NCT03708627?
This trial is sponsored by Johns Hopkins University, which has 1,448 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03708627 being conducted?
This trial has 1 study location across Washington. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Graves Ophthalmopathy
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Extension Study of Two Doses of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
RECRUITING · Phase 2
-
The Effect of Teprotumumab on Thyroid Eye Disease and Thyroid Dysfunction
RECRUITING
-
A Phase 2b, Study of Linsitinib in Subjects With Active, Moderate to Severe Thyroid Eye Disease (TED)
ACTIVE NOT RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI